Tag: UTRF


News

GTx and the University of Tennessee Research Foundation Enter Into Exclusive License Agreement to Develop SARD Drug Candidate to Treat Castration-Resistant Prostate Cancer

|

GTx, Inc. today announced that it has entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation (UTRF) to develop its proprietary selective androgen receptor degrader (SARD) technology which potentially can degrade and inhibit all forms of androgen receptor (AR), including those resistant to current therapies, to inhibit tumor growth in… Read More